Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: Anthy2; Research programme: Th2 cytokines synthesis inhibitor - Y's Therapeutics; Th2 cytokines synthesis inhibitor - Y's Therapeutics; YSTH2-O-AS

Latest Information Update: 23 Sep 2009

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ys Therapeutics
  • Class Antiasthmatics; Small molecules
  • Mechanism of Action Cytokine inhibitors; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Asthma; Atopic dermatitis

Most Recent Events

  • 19 Jul 2005 Phase-II clinical trials in Asthma in Germany (PO)
  • 28 Jul 2004 Discontinued - Preclinical for Atopic dermatitis in Japan (Topical)
  • 27 Jul 2004 Y's Therapeutics has filed an application to begin phase II trials with the Ministry of Health in Germany for Asthma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top